# Apple Tree Partners

Apple Tree Partners is a Private Equity based in New York, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 1999
- **Assets under management:** Undisclosed
- **Website:** www.appletreepartners.com
- **LinkedIn:** https://www.linkedin.com/company/apple-tree-partners

## Regulatory record

- **Reports private funds:** No

## About

Apple Tree Partners (ATP) is a pioneer in life sciences venture capital developing the next generation of transformative biotechnology companies. Founded in 1999, ATP is a leader in life sciences venture capital. The firm creates and invests in science-based companies from pre-IP ideas and asset spinouts through seed stage to IPO and beyond, providing flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.

## Sectors

- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Drug Discovery
- Medical Devices
- Digital Health

## Offices

- London, UK

## People

- Seth Harrison — Founder and Managing Partner
- Anna Batarina — Partner
- Paul Eisenberg — Chief Medical Officer and Venture Partner
- Marie-Therese Afif — Head of Operations

## Questions

### Who runs investment decisions at Apple Tree Partners?

Seth Harrison, founder and managing partner, leads investment decisions and serves on the boards of all portfolio companies created within ATP's current fund. Harrison has invested in life sciences since 1991, previously as a general partner at Oak Investment Partners. He is supported by partners Anna Batarina and venture partners including Paul Da Silva Jardine and Spiros Liras, who bring decades of pharmaceutical R&D leadership.

### How does Apple Tree Partners source its portfolio companies?

ATP primarily creates companies rather than sourcing them externally. The firm works with scientists on pre-IP ideas and spins out assets from existing portfolio company pipelines. Venture partners with deep pharmaceutical discovery backgrounds — several formerly at Pfizer, Amgen, and Novartis — identify and shape programs internally before forming standalone entities around them.

### What investment stages does Apple Tree Partners target?

ATP covers the full spectrum: from pre-IP ideas and seed-stage startups to growth rounds and public-company holdings. The firm explicitly states it invests 'from seed stage through IPO and beyond,' and supports portfolio companies in strategic transactions and business combinations.

### Which sectors does Apple Tree Partners explicitly avoid?

ATP focuses exclusively on life sciences — drug discovery, medical devices, and digital health. The firm does not invest in general technology, consumer, financial services, or industrial sectors. Its website, portfolio, and team composition reflect a single-sector commitment to therapeutics and healthcare innovation.

### What is Apple Tree Partners' known posture on co-investments?

ATP engages in collaborations with pharmaceutical partners — for example, a $1.1B partnership between Aileron Therapeutics and Roche, and a 2025 Novo Nordisk collaboration with Deep Apple Therapeutics. The firm's model also supports co-investment alongside other life-sciences VCs, as seen when Galvanize Therapeutics raised an oversubscribed Series C round in 2025.

## Related profiles

- [Apis Partners](https://altss.com/profile/apis-partners)
- [Arab African Investment Management](https://altss.com/profile/arab-african-investment-management)

---

Last updated: 2026-08-11T15:06:04.815Z

Canonical page: https://altss.com/profile/apple-tree-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology